PNC Financial Services Group Inc. (The) Common Stock vs BIO-TECHNE Corp — how do they compare? PNC Financial Services Group Inc. (The) Common Stock trades at $220 (market cap $86.86B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: PNC Financial Services Group Inc. (The) Common Stock is far larger — about 7.6× BIO-TECHNE Corp's market cap, and PNC Financial Services Group Inc. (The) Common Stock pays the higher dividend (3.67%). Which is the better fit depends on your goals.
| PNC | TECH | |
|---|---|---|
Market Cap | $86.86B | $11.37B |
Volume | 2,044,725 | 3,153,511 |
Sector | Financials | Health |
52-Week High | $256.97 | $72.61 |
52-Week Low | $178.37 | $43.31 |
Enterprise Value | $143.85B | $11.40B |
Dividend Yield | 3.67% | 0.44% |
Typical Hold Time | — | 63 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Trailing returns across standard periods
Latest headlines on both assets
PNC Financial Services Group is a financial services holding company. Its businesses include retail banking, corporate and institutional banking, and asset management.
Read more on PNC →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →